基本信息
views: 52
Career Trajectory
Bio
Our research efforts are focused upon synthesis. The research involves the development of agents to treat a variety of cancers. The heteroarotinoid 1 (X = Y = S; Z = NO2) below has successfully passed all pre-clinical screening for the potential treatment of kidney and ovarian cancer. Plans are to begin PHASE 0 and PHASE 1 clinical trials in 2018 involving humans. Research is continuing with the objective to synthesize modified versions of the clinical agent.
Research Interests
Papers共 231 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2023)
European Journal of Medicinal Chemistry (2019): 16-27
semanticscholar(2016)
Cited0Views0Bibtex
0
0
Load More
Author Statistics
#Papers: 231
#Citation: 3564
H-Index: 33
G-Index: 45
Sociability: 6
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn